Literature DB >> 17005685

Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by high-throughput single-cell analysis of Kaposi's sarcoma-associated herpesvirus infection.

Laura A Adang1, Christopher H Parsons, Dean H Kedes.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV or human herpesvirus-8) is frequently tumorigenic in immunocompromised patients. The average intracellular viral copy number within infected cells, however, varies markedly by tumor type. Since the KSHV-encoded latency-associated nuclear antigen (LANA) tethers viral episomes to host heterochromatin and displays a punctate pattern by fluorescence microscopy, we investigated whether accurate quantification of individual LANA dots is predictive of intracellular viral genome load. Using a novel technology that integrates single-cell imaging with flow cytometry, we found that both the number and the summed immunofluorescence of individual LANA dots are directly proportional to the amount of intracellular viral DNA. Moreover, combining viral (immediate early lytic replication and transcription activator [RTA] and late lytic K8.1) and cellular (syndecan-1) staining with image-based flow cytometry, we were also able to rapidly and simultaneously distinguish among cells supporting latent, immediate early lytic, early lytic, late lytic, and a potential fourth "delayed late" category of lytic replication. Applying image-based flow cytometry to KSHV culture models, we found that de novo infection results in highly varied levels of intracellular viral load and that lytic induction of latently infected cells likewise leads to a heterogeneous population at various stages of reactivation. These findings additionally underscore the potential advantages of studying KSHV biology with high-throughput analysis of individual cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005685      PMCID: PMC1617294          DOI: 10.1128/JVI.01156-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells.

Authors:  R N Shaw; J L Arbiser; M K Offermann
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

2.  Functional organization of MIR2, a novel viral regulator of selective endocytosis.

Authors:  David Jesse Sanchez; Laurent Coscoy; Don Ganem
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

3.  The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors.

Authors:  Ling Wang; Naohiro Wakisaka; Christine C Tomlinson; Scott M DeWire; Stuart Krall; Joseph S Pagano; Blossom Damania
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

4.  Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus.

Authors:  Costin Tomescu; Wai K Law; Dean H Kedes
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998.

Authors:  Silvia Franceschi; Luigino Dal Maso; Patrizio Pezzotti; Jerry Polesel; Claudia Braga; Pierluca Piselli; Diego Serraino; Giovanna Tagliabue; Massimo Federico; Stefano Ferretti; Vincenzo De Lisi; Francesco La Rosa; Ettore Conti; Mario Budroni; Gianni Vicario; Silvano Piffer; Franco Pannelli; Adriano Giacomin; Francesco Bellù; Rosario Tumino; Mario Fusco; Giovanni Rezza
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09-01       Impact factor: 3.731

6.  Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile.

Authors:  Richard G Jenner; Karine Maillard; Nicola Cattini; Robin A Weiss; Chris Boshoff; Richard Wooster; Paul Kellam
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

7.  Small internal deletions in the human cytomegalovirus IE2 gene result in nonviable recombinant viruses with differential defects in viral gene expression.

Authors:  Elizabeth A White; Charles L Clark; Veronica Sanchez; Deborah H Spector
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

8.  Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator.

Authors:  Hiroyuki Nakamura; Michael Lu; Yousang Gwack; John Souvlis; Steven L Zeichner; Jae U Jung
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover.

Authors:  Britt Glaunsinger; Don Ganem
Journal:  Mol Cell       Date:  2004-03-12       Impact factor: 17.970

10.  Kaposi's sarcoma-associated herpesvirus glycoprotein K8.1 is dispensable for virus entry.

Authors:  Rafael E Luna; Fuchun Zhou; Abolgashem Baghian; Vladimir Chouljenko; Bagher Forghani; Shou-Jiang Gao; Konstantin G Kousoulas
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more
  30 in total

1.  Regulation of Nm23-H1 and cell invasiveness by Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhiqiang Qin; Lu Dai; Bryan Toole; Erle Robertson; Chris Parsons
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  KSHV attachment and entry are dependent on αVβ3 integrin localized to specific cell surface microdomains and do not correlate with the presence of heparan sulfate.

Authors:  H Jacques Garrigues; Laura K DeMaster; Yelena E Rubinchikova; Timothy M Rose
Journal:  Virology       Date:  2014-07-24       Impact factor: 3.616

3.  Visualization of molecular biology: The LANA tether.

Authors:  Vaibhav Jain; Rolf Renne
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-24       Impact factor: 11.205

4.  Kaposi sarcoma-associated herpesvirus (KSHV) induces a functional tumor-associated phenotype for oral fibroblasts.

Authors:  Lu Dai; Zhiqiang Qin; Michael Defee; Bryan P Toole; Keith L Kirkwood; Chris Parsons
Journal:  Cancer Lett       Date:  2011-12-17       Impact factor: 8.679

5.  mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.

Authors:  Debasmita Roy; Sang-Hoon Sin; Amy Lucas; Raman Venkataramanan; Ling Wang; Anthony Eason; Veenadhari Chavakula; Isaac B Hilton; Kristen M Tamburro; Blossom Damania; Dirk P Dittmer
Journal:  Cancer Res       Date:  2013-02-04       Impact factor: 12.701

6.  Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.

Authors:  Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

7.  Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress.

Authors:  Zhiqiang Qin; Eduardo Freitas; Roger Sullivan; Sarumathi Mohan; Rocky Bacelieri; Drake Branch; Margaret Romano; Patricia Kearney; Jim Oates; Karlie Plaisance; Rolf Renne; Johnan Kaleeba; Chris Parsons
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

8.  Tracking expression and subcellular localization of RNA and protein species using high-throughput single cell imaging flow cytometry.

Authors:  Sumit Borah; Lisa A Nichols; Lynn M Hassman; Dean H Kedes; Joan A Steitz
Journal:  RNA       Date:  2012-06-28       Impact factor: 4.942

9.  Distinct roles for extracellular signal-regulated kinase 1 (ERK1) and ERK2 in the structure and production of a primate gammaherpesvirus.

Authors:  Evonne N Woodson; Dean H Kedes
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

10.  RNA editing of the human herpesvirus 8 kaposin transcript eliminates its transforming activity and is induced during lytic replication.

Authors:  Sharon Z Gandy; Sarah D Linnstaedt; Sumitra Muralidhar; Kathleen A Cashman; Leonard J Rosenthal; John L Casey
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.